Simulations of Levothyroxine Bioavailability Using a Single-Dose Study Protocol.

Area of Science:

• Pharmacokinetics
• Drug bioavailability
• Thyroid hormone replacement therapy

Background:

• Accurate computation of oral levothyroxine bioavailability parameters is challenging due to its long pharmacokinetic half-life and endogenous hormone secretion.
• Existing methods face limitations in precisely determining bioavailability.
• A novel approach using a single, supraphysiologic oral dose was proposed to simplify calculations.

Purpose of the Study:

• To assess the potential methodological errors associated with a proposed nonstandard protocol for oral levothyroxine bioavailability assessment.
• To evaluate the reliability of using a single, supraphysiologic oral dose and 48-hour serum concentration-time curve (AUC) measurements.
• To determine the accuracy of pharmacokinetic simulations in predicting errors in AUC computations.

Main Methods:

• Pharmacokinetic simulations were performed to model levothyroxine absorption and elimination.
• The proposed method involved a single, supraphysiologic oral levothyroxine dose.
• Area under the serum concentration versus time curves (AUC) were calculated over 48 hours post-administration.

Main Results:

• Pharmacokinetic simulations indicated a potential methodological error of approximately 1% in AUC computations using the proposed protocol.
• The supraphysiologic dosing strategy appears generally reliable for standard patient populations.
• However, simulations revealed that patients with extremely short levothyroxine half-lives (less than 2-3 days) may experience larger errors in AUC values.

Conclusions:

• The proposed single, supraphysiologic oral levothyroxine dosing protocol is generally accurate for bioavailability parameter computation, with minimal simulated error.
• The method's reliability is compromised in patients with significantly shortened levothyroxine half-lives, necessitating careful consideration.
• Further validation may be required for specific patient subgroups with rapid drug clearance or endogenous hormone turnover.